Predictive potential

How Geno plans to guide lung cancer treatment in China with CytoploRare

CytoploRare from Geno Biotech Co. Ltd. is the first circulating tumor cell test approved in China to diagnose lung cancer. With greater sensitivity and specificity in the indication than other CTC tests that are used off label, CytoploRare could be expanded to guide treatment decisions, particularly in populations with limited access to targeted therapies.

CEO Wei He told BioCentury Geno plans to develop the test to predict responses to chemotherapy as well as targeted therapies, because many patients in China cannot afford targeted therapies.

"Prediction is currently much more meaningful than prognosis because we have so many treatment choices. We want

Read the full 1037 word article

How to gain access

Continue reading with a
two-week free trial.